Sugi Predict

Sugi Predict / Compounds / SCHEMBL19948901

SCHEMBL19948901

SCHEMBL19948901

COC(=O)c1nc(CBr)cs1

nearest known ligand 0.41

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.38
▸ KMT2A Q03164 6/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.36
▸ MEN1 O00255 3/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ KDM4E B2RXH2 3/20 0.33
▸ CES1 P23141 1/20 0.33
▸ MAOA P21397 1/20 0.33
▸ ACHE P22303 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ HDAC1 Q13547 1/20 0.33
▸ HDAC6 Q9UBN7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17716400 0.84 ALDH1A1 (0.39) ALDH1A1KMT2ANPSR1MEN1SMN1; SMN2
SCHEMBL4721794 0.83 ALDH1A1 (0.46) ALDH1A1KMT2ANPSR1MEN1SMN1; SMN2
SCHEMBL128540 0.83 ALDH1A1 (0.41) ALDH1A1KMT2ANPSR1MEN1SMN1; SMN2
SCHEMBL14825340 0.83 SMN1; SMN2 (0.53) ALDH1A1KMT2ASMN1; SMN2MAPTKDM4E
SCHEMBL5034313 0.82 ALDH1A1 (0.39) ALDH1A1KMT2ANPSR1MEN1SMN1; SMN2
SCHEMBL2218602 0.81 KMT2A (0.38) ALDH1A1KMT2ANPSR1MEN1MAPT
SCHEMBL28170691 0.77 PLA2G4A (0.39) ALDH1A1KMT2ANPSR1MEN1SMN1; SMN2
SCHEMBL1682676 0.77 GRM5 (0.48) ALDH1A1KMT2ANPSR1MEN1SMN1; SMN2
SCHEMBL162705 0.74 ALDH1A1 (0.42) ALDH1A1KMT2ANPSR1MEN1SMN1; SMN2
SCHEMBL129265 0.74 MAPT (0.43) ALDH1A1KMT2ANPSR1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688790-A1 MACROCYCLIC RAS INHIBITORS Revolution Medicines, Inc. (US) 2026-02-11 — — EP disclosed
US-20260028353-A1 MACROCYCLIC RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT 2026-01-29 — — US disclosed
WO-2024211712-A1 CONDENSED MACROCYCLIC COMPOUNDS AS RAS INHIBITORS Revolution Medicines, Inc. (US) 2024-10-10 — — WO disclosed
EP-4426681-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS Sitryx Therapeutics Limited (GB) 2024-09-11 — — EP disclosed
CN-118317951-A Phthalazine derivatives as pyruvate kinase modulators 西特瑞治疗有限公司 2024-07-09 — — CN disclosed
CN-117003762-A Piperidine formamide aza indane derivative, preparation method and application thereof 熙源安健医药（上海）有限公司 2023-11-07 — — CN disclosed
WO-2023079294-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS SITRYX THERAPEUTICS LIMITED (GB) 2023-05-11 — — WO disclosed
WO-2023079294-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS SITRYX THERAPEUTICS LIMITED (GB) 2023-05-11 — — WO disclosed
CN-110234656-B Exonucleotidase inhibitors and methods of use thereof 卡利泰拉生物科技公司 2023-02-28 — — CN disclosed
EP-3668512-B1 PYRUVATE KINASE MODULATORS AND USE THEREOF AGIOS PHARMACEUTICALS INC (US) 2023-02-15 — — EP disclosed
US-20200087310-A1 Ectonucleotidase Inhibitors and Methods of Use Thereof ANTENGENE THERAPEUTICS LIMITED (CN) 2020-03-19 — — US disclosed
US-10570167-B2 Ectonucleotidase inhibitors and methods of use thereof CALITHERA BIOSCIENCES, INC. (US) 2020-02-25 — — US disclosed
US-10472364-B2 Ectonucleotidase inhibitors and methods of use thereof CALITHERA BIOSCIENCES, INC. (US) 2019-11-12 — — US disclosed
EP-3558998-A1 ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF Calithera Biosciences, Inc. (US) 2019-10-30 — — EP disclosed
CN-110234656-A Extracellular nucleotides enzyme inhibitor and its application method 卡利泰拉生物科技公司 2019-09-13 — — CN disclosed
EP-3510040-A1 ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF Calithera Biosciences, Inc. (US) 2019-07-17 — — EP disclosed
US-20180186827-A1 Ectonucleotidase Inhibitors and Methods of Use Thereof ANTENGENE THERAPEUTICS LIMITED (CN) 2018-07-05 — — US disclosed
WO-2018119284-A1 ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF CALITHERA BIOSCIENCES, INC. (US) 2018-06-28 — — WO disclosed
WO-2018049145-A1 ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF CALITHERA BIOSCIENCES, INC. (US) 2018-03-15 — — WO disclosed
US-20180072742-A1 ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF ANTENGENE THERAPEUTICS LIMITED (CN) 2018-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180186827-A1 Ectonucleotidase Inhibitors and Methods of Use Thereof NT5E, ENTPD5, NT5C2 ALDH1A1 527/4885KMT2A 3055/4885NPSR1 199/4885
US-20260028353-A1 MACROCYCLIC RAS INHIBITORS KRAS, NRAS, HRAS ALDH1A1 3620/4885KMT2A 3068/4885NPSR1 4632/4885
US-20180072742-A1 ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF NT5E, ENTPD5, NT5C2 ALDH1A1 527/4885KMT2A 3055/4885NPSR1 199/4885
US-10472364-B2 Ectonucleotidase inhibitors and methods of use thereof ENTPD5, NT5E, ENTPD1 ALDH1A1 367/4885KMT2A 2369/4885NPSR1 858/4885
US-10570167-B2 Ectonucleotidase inhibitors and methods of use thereof NT5E, ENTPD5, NT5C2 ALDH1A1 527/4885KMT2A 3055/4885NPSR1 199/4885
US-20200087310-A1 Ectonucleotidase Inhibitors and Methods of Use Thereof NT5E, ENTPD5, NT5C2 ALDH1A1 527/4885KMT2A 3055/4885NPSR1 199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.